TULSA, Okla. — The ACTIV-2 clinical trial, which is investigating treatments for early COVID-19, announces the addition of a new agent to the study. Developed by Brii Biosciences, BRII-196 and BRII-198 are monoclonal antibodies that each target a different part of SARS-CoV-2, the virus that causes COVID-19. Researchers hope that the combination of the two therapeutics will improve efficacy and reduce the likelihood that the virus will develop resistance to the treatment.
Study participants will be randomized to receive either the combination agent or a placebo. ACTIV-2 is part of the National Institute of Health’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, sponsored by the National Institute of Allergy and Infectious Diseases, and is designed and led by the AIDS Clinical Trial Group (ACTG).
ACTIV-2 also receives support from Operation Warp Speed.
Researchers say COVID-19 treatments that can speed recovery and prevent people from progressing to advanced disease, requiring hospitalization, and transmitting SARS-CoV-2 are desperately needed. While effective vaccines are essential to prevent COVID-19, treatments also play a vital role in ending the pandemic. Vaccine roll-out will take time and not everyone will want or be able to get one in the near term. Clinical trials are vital to discovering such treatments and only work when enough people volunteer to participate.
Ascension St. John Clinical Research Institute in Tulsa is among 94 other sites across the U.S.
Find other locations here.
To qualify for ACTIV-2, individuals in the Tulsa area must have tested positive for SARS-CoV-2 in the outpatient setting and started experiencing symptoms within 10 days of enrolling.
The trial is committed to enrolling individuals most impacted by COVID-19, and, to date, nearly one-third of study participants have been Latinx. The ACTG has launched initiatives to increase inclusion of people of color, including establishing research sites in locations where these communities receive care.
To learn more or enroll, visit www.ACTIV-2.org or call 877-345-881 or in the Tulsa area, call 918-744-3426.